Reporting Problems with Medication Switches
The Foundation maintains that the individual and physician should be notified and give their consent before a switch in medications is made, whether it involves generic substitution for brand name products, or generic to generic substitutions. This is a long-standing position of the Foundation which has been communicated to the Food and Drug Administration (FDA). The Foundation continues to advocate for policy changes regarding this issue.
The FDA encourages people with epilepsy and physicians to report any breakthrough seizures resulting from switching formulations of a product to the FDA's MedWatch program. For information, call 1-800-FDA-1088 or visit the web site at http://www.fda.gov/medwatch.
